Pharmaceuticals, Biotechnology and Life Sciences
Operating loss significantly improved by reducing R&D expenses and generating revenues from LUMEVOQ® ATU in France
Ramp up of Sales & Marketing in preparation of the expected commercial launch of LUMEVOQ® in Europe early 2022
Successful r…
Operating loss significantly improved by reducing R&D expenses and generating revenues from LUMEVOQ® ATU in France
Ramp up of Sales & Marketing in preparation of the expected commercial launch of LUMEVOQ® in Europe early 2022
Successful r…
Operating loss significantly improved by reducing R&D expenses and generating revenues from LUMEVOQ® ATU in France
Ramp up of Sales & Marketing in preparation of the expected commercial launch of LUMEVOQ® in Europe early 2022
Successful r…
Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models
DUBLIN & TOKUSHIMA, Japan–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/C…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021…
Creates Leading Immunotherapy and Cell Therapy Company
CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock mer…
Creates Leading Immunotherapy and Cell Therapy Company
CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock mer…
Creates Leading Immunotherapy and Cell Therapy Company
CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock mer…
Creates Leading Immunotherapy and Cell Therapy Company
CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock mer…
Creates Leading Immunotherapy and Cell Therapy Company
CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock mer…